---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-053844"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:26:50.209397+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics stockholders elect directors and approve equity plan at 2025 annual meeting

## Summary
- Stockholders elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors with 17.7M, 22.1M, and 22.1M votes for, respectively.
- Ratification of Ernst & Young as independent auditor for fiscal 2025 was approved with 29.3M votes for, 147,664 against, 327,362 abstentions.
- Advisory vote on executive compensation passed with 20.4M for, 134,110 against, 2.1M abstentions, and 7.2M broker non-votes.
- Amendment to the 2024 Equity Incentive Plan was approved with 21.3M for, 907,425 against, 365,697 abstentions, and 7.2M broker non-votes.
- Over 38.5M shares were outstanding as of the April 16, 2025 record date; meeting held June 11, 2025.

## SEC filing metadata
- accession: 0001213900-25-053844
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025053844/0001213900-25-053844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025053844/ea0245492-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-053844
- JSON: https://secwatch.observer/filing/0001213900-25-053844.json
- Plain text: https://secwatch.observer/filing/0001213900-25-053844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.